Cross protection studies after the use of live attenuated IBV vaccines Nobilis**R IB 4-91 and Nobilis**R IB Ma5 (Massachusetts type)
2003
Kuehne, P.J.G. (Intervet International BV, Boxmeer (Netherlands))
In recent years, much effort has been applied to determining the particular serotype of new isolates of infectious bronchitis (IB) virus. This information is of considerable value for research purposes and particularly for understanding the epidemiology of IB infections. With the increasing prevalence of different antigenic types of IB virus worldwide, the problem of designing vaccination programs to control each new serotype becomes increasingly difficult. Furthermore, it is both undesirable and unnecessary to consider developing a new live-attenuated vaccine for each new emerging IB serotype as shown in the results presented in this article. These results confirm the validity of the concept of protectotypes, which from a practical point of view is more relevant, and show that, with IB, in vivo protection is much broader than the results of in vitro serum neutralisation tests might suggest. The results presented here clearly show that the use of the two live-attenuated IB vaccine strains 4-91 and Ma5, developed from different IB serotypes, considerably broaden the protection achieved against challenge with a wide variety of antigenically different IBVs prevalent worldwide.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par Fundamental Library of Latvia University of Life Sciences and Technologies
Découvrez la collection de ce fournisseur de données dans AGRIS